
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Divisions of Cancer Prevention [P. M. M.] and Cancer Epidemiology and Genetics [R. B. H., M. G-C., N. E. C., N. R.]; National Cancer Institute, Bethesda, Maryland 20892; Department of Environmental and Occupational Medicine, University of Aarhus, Aarhus, Denmark DK-8000 [H. A., H. O.]; Center for Clinical Pharmacology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261 [R. A. B., M. R.]; Department of Clinical Pharmacology of the Charité 74, Humboldt University, Berlin D-10098 Germany [J .B., I. R.]; Department of Pharmacology and Therapeutics, Graduate School of Clinical Pharmacy, Kumamoto University, Kumamoto 862-0973 Japan [T. I.]; Department of Toxicology, Gazi University, Ankara 06100 Turkey [A. E. K.]; Hospital Clinico De San Carlos, Departamento de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain [J. M. L.]; Surgical Department, Urologic Unit, Randers Hospital, Randers DK-8900 Denmark [S. M.]; and Unit of Cancer Epidemiology, University of Turin, 10126 Turin, Italy [P. V.]
Tobacco use is an established cause of bladder cancer. The ability to detoxify aromatic amines, which are present in tobacco and are potent bladder carcinogens, is compromised in persons with the N-acetyltransferase 2 slow acetylation polymorphism. The relationship of cigarette smoking with bladder cancer risk therefore has been hypothesized to be stronger among slow acetylators. The few studies to formally explore such a possibility have produced inconsistent results, however. To assess this potential gene-environment interaction in as many bladder cancer studies as possible and to summarize results, we conducted a meta-analysis using data from 16 bladder cancer studies conducted in the general population (n = 1999 cases). Most had been conducted in European countries. Because control subjects were unavailable for a number of these studies, we used a case-series design, which can be used to assess multiplicative gene-environment interaction without inclusion of control subjects. A case-series interaction odds ratio (OR) >1.0 indicates that the relationship of cigarette smoking and bladder cancer risk is stronger among slow acetylators as compared with rapid acetylators. We observed an interaction between smoking and N-acetyltransferase 2 slow acetylation (OR, 1.3; 95% confidence interval, 1.01.6) that was somewhat stronger when analyses were restricted to studies conducted in Europe (OR, 1.5; confidence interval, 1.11.9), a pooling that included nearly 80% of the collected data. Using the predominantly male European study population and assuming a 2.5-fold elevation in bladder cancer risk from smoking, we estimated that the population attributable risk percent was 35% for slow acetylators who had ever smoked and 13% for rapid acetylators who had ever smoked. These results suggest that the relationship of smoking and bladder cancer is stronger among slow acetylators than among rapid acetylators.
This article has been cited by other articles:
![]() |
L. Tang, G. R. Zirpoli, K. Guru, K. B. Moysich, Y. Zhang, C. B. Ambrosone, and S. E. McCann Consumption of Raw Cruciferous Vegetables is Inversely Associated with Bladder Cancer Risk Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 938 - 944. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sanderson, G. Salanti, and J. Higgins Joint Effects of the N-Acetyltransferase 1 and 2 (NAT1 and NAT2) Genes and Smoking on Bladder Carcinogenesis: A Literature-based Systematic HuGE Review and Evidence Synthesis Am. J. Epidemiol., October 1, 2007; 166(7): 741 - 751. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Ochs-Balcom, G. Wiesner, and R. C. Elston A Meta-Analysis of the Association of N-Acetyltransferase 2 Gene (NAT2) Variants with Breast Cancer Am. J. Epidemiol., August 1, 2007; 166(3): 246 - 254. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Kellen, M. Hemelt, K. Broberg, K. Golka, V. N. Kristensen, R. J. Hung, G. Matullo, R. D. Mittal, S. Porru, A. Povey, et al. Pooled Analysis and Meta-analysis of the Glutathione S-Transferase P1 Ile 105Val Polymorphism and Bladder Cancer: A HuGE-GSEC Review Am. J. Epidemiol., June 1, 2007; 165(11): 1221 - 1230. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Rothman, M. Garcia-Closas, and D. W Hein Commentary: Reflections on G. M. Lower and colleagues' 1979 study associating slow acetylator phenotype with urinary bladder cancer: meta-analysis, historical refinements of the hypothesis, and lessons learned Int. J. Epidemiol., February 1, 2007; 36(1): 23 - 28. [Full Text] [PDF] |
||||
![]() |
J. J. Wong-You-Cheong, P. J. Woodward, M. A. Manning, and I. A. Sesterhenn From the Archives of the AFIP: Neoplasms of the Urinary Bladder: Radiologic-Pathologic Correlation RadioGraphics, March 1, 2006; 26(2): 553 - 580. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Broberg, J. Bjork, K. Paulsson, M. Hoglund, and M. Albin Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer Carcinogenesis, July 1, 2005; 26(7): 1263 - 1271. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Schabath, G. L. Delclos, H. B. Grossman, Y. Wang, S. P. Lerner, R. M. Chamberlain, M. R. Spitz, and X. Wu Polymorphisms in XPD Exons 10 and 23 and Bladder Cancer Risk Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 878 - 884. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Grigorenko The Inherent Complexities of Gene-Environment Interactions J. Gerontol. B. Psychol. Sci. Soc. Sci., March 1, 2005; 60(suppl_Special_Issue_1): 53 - 64. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M Gatto, U. B Campbell, A. G Rundle, and H. Ahsan Further development of the case-only design for assessing gene-environment interaction: evaluation of and adjustment for bias Int. J. Epidemiol., October 1, 2004; 33(5): 1014 - 1024. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Deitz, N. Rothman, T. R. Rebbeck, R. B. Hayes, W.-H. Chow, W. Zheng, D. W. Hein, and M. Garcia-Closas Impact of Misclassification in Genotype-Exposure Interaction Studies: Example of N-Acetyltransferase 2 (NAT2), Smoking, and Bladder Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2004; 13(9): 1543 - 1546. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lin, M. R. Spitz, Y. Wang, M. B. Schabath, I. P. Gorlov, L. M. Hernandez, P. C. Pillow, H. B. Grossman, and X. Wu Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study Carcinogenesis, September 1, 2004; 25(9): 1639 - 1647. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Ansell, M. J. Ackerman, J. L. Black, L. R. Roberts, and A. Tefferi Primer on Medical Genomics Part VI: Genomics and Molecular Genetics in Clinical Practice Mayo Clin. Proc., March 1, 2003; 78(3): 307 - 317. [Abstract] [PDF] |
||||
![]() |
M. C. Stern, L. R. Johnson, D. A. Bell, and J. A. Taylor XPD Codon 751 Polymorphism, Metabolism Genes, Smoking, and Bladder Cancer Risk Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 1004 - 1011. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Engel, E. Taioli, R. Pfeiffer, M. Garcia-Closas, P. M. Marcus, Q. Lan, P. Boffetta, P. Vineis, H. Autrup, D. A. Bell, et al. Pooled Analysis and Meta-analysis of Glutathione S-Transferase M1 and Bladder Cancer: A HuGE Review Am. J. Epidemiol., July 15, 2002; 156(2): 95 - 109. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Vineis, D. Marinelli, H. Autrup, J. Brockmoller, I. Cascorbi, A. K. Daly, K. Golka, H. Okkels, A. Risch, N. Rothman, et al. Current Smoking, Occupation, N-Acetyltransferase-2 and Bladder Cancer: A Pooled Analysis of Genotype-based Studies Cancer Epidemiol. Biomarkers Prev., December 1, 2001; 10(12): 1249 - 1252. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Albert, D. Ratnasinghe, J. Tangrea, and S. Wacholder Limitations of the Case-only Design for Identifying Gene-Environment Interactions Am. J. Epidemiol., October 15, 2001; 154(8): 687 - 693. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Cascorbi, I. Roots, and J. Brockmoller Association of NAT1 and NAT2 Polymorphisms to Urinary Bladder Cancer: Significantly Reduced Risk in Subjects with NAT1*10 Cancer Res., July 1, 2001; 61(13): 5051 - 5056. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |